

**KURZPROTOKOLL**  
**CA209-577**

<b>Öffentlicher Titel</b>	Phase III Studie zu Nivolumab bei Ösophaguskarzinom nach Resektion
<b>Wissenschaftl. Titel</b>	A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer
<b>Kurztitel</b>	CA209-577
<b>Studienart</b>	multizentrisch, Therapiestudie, randomisiert, Pharma-Studie, doppelblind, zweiarmig, kontrolliert
<b>Studienphase</b>	Phase III
<b>Erkrankung</b>	Verdauung: Magen-/Speiseröhrenkrebs (Magen-/Ösophaguskarzinom): adjuvant
<b>Einschlusskriterien</b>	<ul style="list-style-type: none"><li>- subjects diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction</li><li>- subjects completed pre-operative chemoradiotherapy followed by surgery</li><li>- subjects diagnosed with residual pathologic disease after being surgically rendered free of disease with negative margins following complete resection</li></ul>
<b>Ausschlusskriterien</b>	<ul style="list-style-type: none"><li>- subjects diagnosed with cervical esophageal carcinoma</li><li>- subjects diagnosed with Stage IV resectable disease</li><li>- subjects who did not receive concurrent chemoradiotherapy prior to surgery</li></ul>
<b>Alter</b>	18 Jahre und älter
<b>Prüfzentren</b>	<b>Universitätsklinikum Frankfurt</b> (Rekrutierung beendet) UCT-Zentrale Theodor-Stern-Kai 7 60590 Frankfurt am Main Christina Henkel Tel: 069 6301-83787 Fax: 069 6301-83788 <a href="mailto:christina.henkel@kgu.de">christina.henkel@kgu.de</a>
<b>Sponsor</b>	Bristol-Myers Squibb
<b>Registrierung in anderen Studienregistern</b>	ClinicalTrials.gov NCT02743494 (primäres Register) EudraCT 2015-005556-10